Effects of erythropoietin on the clinical outcomes of patients with acute ST segment elevation myocardial infarction after percutaneous coronary intervention: A meta-analysis .
To investigate the effects of erythropoietin (EPO) on the clinical outcomes of patients with acute ST segment elevation myocardial infarction (STEMI) after percutaneous coronary intervention (PCI). We collected randomized controlled studies conducted before April 15, 2017, and performed a meta-analysis using RevMan5.3 software. Compared with the conventional revascularization group, mortality (RR = 0.79; 95% Cl, 0.42 - 1.50; p = 0.47), stroke events (RR = 2.63; 95% Cl, 0.70 - 9.85; p = 0.15), recurrent myocardial infarction (RR = 0.99; 95% Cl, 0.44 - 2.20; p = 0.98), and other clinical endpoints were not significantly different in the EPO group. However, subgroup analysis showed a marginally significant difference between the high-dose EPO group and the control group (MD = 1.29; 95% CI, 0.02 - 2.56; p = 0.05) in ejection fraction. The administration of EPO has no effects on the clinical outcomes of patients with acute STEMI after PCI, whilst a high dose of EPO may increase patients' ejection fraction. .